FOLH1 and neoplasm: Specifically, a Tz-conjugated prostate-specific membrane antigen (PSMA) targeting ligand, denoted as DOTA-PSMA-Tz, was developed and radiolabeled with radionuclide 68Ga ([68Ga]Ga-PSMA-Tz) or 177Lu ([177Lu]Lu-PSMA-Tz) as example and evaluated for its tumor-targeting effectiveness both in vitro and in vivo.